STOCK TITAN
  1. Home
  2. Sec-filings
  3. NTLA
  4. [Form 4] Intellia Therapeutics, Inc Insider Trading Activity

NTLA Insider Purchase: Director William J. Chase Adds 100K Shares at ~$10.03

Filing Impact
(High)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

William J. Chase, a director of Intellia Therapeutics, Inc. (NTLA), reported an open-market purchase of 100,000 shares of the issuer's common stock on 08/20/2025. The shares were bought in accordance with the company's trading policies at a weighted average price of $10.03, with transaction prices ranging from $9.97 to $10.04. Following the purchase, the reporting person beneficially owned 134,693 shares. The Form 4 was filed as a single-person report and signed by attorney-in-fact James Basta on 08/22/2025.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: A director purchased 100,000 NTLA shares at a $10.03 weighted average, modestly increasing insider ownership.

The reported open-market purchase of 100,000 shares at a weighted average price of $10.03 signals a director-level buying activity completed under company trading policies. The filing shows the director's post-transaction beneficial ownership at 134,693 shares. This is a straightforward Section 16 disclosure with no derivatives, issuances, or option exercises disclosed. The price range ($9.97–$10.04) and the statement that full per-lot pricing details are available on request provide transparency about execution. No other compensatory or non-routine transactions are included.

TL;DR: Transaction complies with trading policies and was properly reported; no governance red flags in the filing.

The Form 4 identifies the reporting person as a director and indicates the purchase was made pursuant to the issuer's trading policies, consistent with Rule 10b5-1 considerations. The filing is complete for a single reporting person, discloses a weighted average price and a price range, and is executed via attorney-in-fact. There are no indications of related-party transfers, derivative transactions, or amendments to prior disclosures in this document.

Insider CHASE WILLIAM J
Role Director
Bought 100,000 shs ($1.00M)
Type Security Shares Price Value
Purchase Common Stock 100,000 $10.03 $1.00M
Holdings After Transaction: Common Stock — 134,693 shares (Direct)
Footnotes (2)
  1. F1. Reflects an open market purchase of shares of the Issuer's common stock by the Reporting Person in accordance with the Issuer's trading policies.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.97 to $10.04, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased by the reporting person on August 20, 2025 at each separate price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CHASE WILLIAM J
(Last) (First) (Middle)
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET, SUITE 130
(Street)
CAMBRIDGE MA 02139
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/20/2025 P(1) 100,000 A $10.03(2) 134,693 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects an open market purchase of shares of the Issuer's common stock by the Reporting Person in accordance with the Issuer's trading policies.
2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.97 to $10.04, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased by the reporting person on August 20, 2025 at each separate price.
/s/ James Basta, attorney-in-fact 08/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR